Sign in to view Amy’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Greater Chicago Area
Contact Info
Sign in to view Amy’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
1K followers
500+ connections
Sign in to view Amy’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Amy
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Amy
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Sign in to view Amy’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Websites
- Personal Website
- https://twitter.com/paller_lab
- Personal Website
- https://www.instagram.com/paller_lab/
Activity
Sign in to view Amy’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
-
Fantastic to team with the Keith Choate group in moving forward research related to ichthyosis. Proud of the team of seven from Northwestern, who…
Fantastic to team with the Keith Choate group in moving forward research related to ichthyosis. Proud of the team of seven from Northwestern, who…
Shared by Amy Paller
-
Announcing the newest members of the Simpson Lab at University of Washington Department of Dermatology at UW Medicine. Arti Parihar, PhD, joined us…
Announcing the newest members of the Simpson Lab at University of Washington Department of Dermatology at UW Medicine. Arti Parihar, PhD, joined us…
Liked by Amy Paller
-
Hopefully showing the high extent of stigma and mental health issues related to skin disease in such a large group of children will finally open eyes…
Hopefully showing the high extent of stigma and mental health issues related to skin disease in such a large group of children will finally open eyes…
Shared by Amy Paller
Experience & Education
-
Northwestern University - The Feinberg School of Medicine
****** *. ****** ********* *** ***** ** ***********
-
*** & ****** *. ***** ********'* ******** ** *******
********* ** ********** *** ***********
-
******** **********
****** ** ******** - ** ********
-
View Amy’s full experience
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View Amy’s full profile
Sign in
Stay updated on your professional world
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Other similar profiles
-
April Armstrong, MD MPH
Los Angeles, CAConnect -
Tina Bhutani, MD, MAS
Board Certified Dermatologist, Clinical Researcher, and CEO of Synergy Dermatology
San Francisco, CAConnect -
Hee Sup Shin
Assistant Professor at the University of Missouri, Kansas City
Chicago, ILConnect -
Jonathan Silverberg
Director of Clinical Research at The George Washington University School of Medicine and Health Sciences
Greater Chicago AreaConnect -
Mitchell Pet
Plastic Surgeon at Washington University in St. Louis
St Louis, MOConnect -
Joel M Gelfand MD MSCE
Philadelphia, PAConnect -
Dedee Murrell
Professor & Head, Department of Dermatology, St George Hospital, University of NSW, Sydney
Sydney, NSWConnect -
Brett King
New Haven, CTConnect -
Emma Guttman
New York City Metropolitan AreaConnect -
Joyce Teng
Palo Alto, CAConnect -
Zakia Rahman, MD, FAAD
Palo Alto, CAConnect -
Adam Friedman
Bronx, NYConnect -
Joseph F. Merola, M.D. MMSc
Chair, Dermatology; Professor of Dermatology, Medicine and Rheumatology; UT Southwestern Medical Center
Boston, MAConnect -
Keyvan Nouri
Miami-Fort Lauderdale AreaConnect -
Peter Lio
Greater Chicago AreaConnect -
James Q. Del Rosso, DO
Las Vegas, NVConnect -
Gil Yosipovitch
Professor Stiefel Chair of Medical Dermatology
Miami, FLConnect -
Kyle Jeray
MD at Stedman Hawkins
Greenville, SCConnect -
Stuart Rosenberg
MD at San Francisco Urology
Atherton, CAConnect -
Gundeep Singh
MD Owner at Marshall Cardiology
Chandler, AZConnect
Explore more posts
-
OncLive
ICYMI: In this episode of OncLive On Air, Ryan Merkow, MD, MS, of the University of Chicago Medicine Comprehensive Cancer Center, and Louise Catherine Connell, MB BCh BAO, BMedSc, of Memorial Sloan Kettering Cancer Center, discuss the use of HAI therapy for patients with colorectal cancer. https://lnkd.in/eZsDpEin
3 -
Matthew Goetz
An important question in the adjuvant treatment of high risk ER+/HER2 negative breast cancer with abemacicib: is the benefit of abemacicib compromised in those that require dose reductions? A secondary analysis of MonarchE suggests that reducing the dose to manage side effects did not alter efficacy. Clinicians should utilize dose modifications when necessary to maximize adherence. https://lnkd.in/gz9xfEWW
623 Comments -
Thuy Ngo
Registration is opened for THE EARLY DETECTION OF CANCER CONFERENCE sponsored by CRUK, Stanford's Canary Center, and OHSU's Knight Cancer Institute. I am delight to serve as a chair along side with Dr. Utkan Demirci at Stanford and Dr. Sam Janes at University of College London. KEYNOTE SPEAKERS: * Peter Sasieni, King’s College London - Revolutionising cancer screening * Steve Quake, Stanford University - New approaches to early detection of Cancer * Azra Raza, Columbia University - The First Cell: Route for early detection and prevention SCIENTIFIC SECTIONS: * How is biology informing early detection? * Emerging technologies for cancer early detection * Insights from Early Detection Trials * Artificial Intelligence – promises vs. reality for early detection PANEL DISCUSSION: * Global challenges in cancer early detection regarding the differences in biological and environmental factors and healthcare system * Investing into the future: From Lab to Clinic * The future of evaluation of cancer screening technologies NETWORKING: From Lab to Clinic Networking & GREAT DEBATE
31 -
Douglas Flora, MD, LSSBB, FACCC
So many great people are dedicated to eradicating cancer, across so many industries. To make real progress, it’s going to take our collective talents, creativity, and a willingness to think outside the box (occasionally). 2.1 million cancer patients will be diagnosed here this year, and they don’t have time for politics, nihilism, or small thinking. It’s too late to save Daniel Flora MD, PharmD, or Dave Flora’s mom, Same for David Penberthy and Scott Penberthy. We must do better. My call to action as so many of us are thinking about moms lost: take a step today to get involved, and do what you can to help us get there. That means ACTIVELY supporting more advocacy, research, screening and prevention, anywhere you can. Solid progress is being made, but so much left to do. Fighting cancer is a team sport. Some easy steps: Join American Cancer Society Cancer Action Network (ACS CAN): https://lnkd.in/gWhKQ78c Engage with Association of Cancer Care Centers: https://lnkd.in/g4tXF29i Support American Cancer Society events, fundraise, spread the information they share on here w your networks: https://lnkd.in/gG5sUZK4 Please add any organizations you think we should be following or supporting that are near and dear to you in the comments below. #brothersfigtingcancer Sanjay Juneja, M.D. Olalekan Ajayi PharmD MBA FACCC AI in Precision Oncology Mary Ann Liebert, Inc. St. Elizabeth Healthcare St. Elizabeth Physicians
7714 Comments -
John Wilson
I’d like to see a response to this statement Jason. The key is to move from pre-clinical to clinical at warp speed. G-Rex is the only technology that can scale linearly from pre-clinical development to commercial manufacturing without changes in phenotype or critical process parameters. Why is that important? Because it saves about one year of time and most companies are burning through 5% to 10% of their venture money per month. Hence, in the current funding environment, one year of saved time creates a highly favorable impact on company longevity.
151 Comment -
Christopher Bunick
Dr. Naiem Issa and I are excited to share our newly published article in JAAD addressing deficiencies in the 2024 acne vulgaris treatment guidelines. We provide compelling evidence for why clascoterone and sarecycline should have strong recommendations in the guidelines. Moreover, we demonstrate that the wholesale acquisition cost (WAC) for these branded medicines is comparable to other branded acne medicines, not outliers as the guidelines would suggest. We hope that the dermatology community will reconsider the excellent utility of clascoterone and sarecycline in addressing the major unmet needs in acne treatment that remain since the publication of the AAD 2024 acne guidelines. https://lnkd.in/ekZaqkxP
521 Comment -
Stephen R. Grobmyer, MD
New US Preventive Services Task Force recommendations on breast cancer screening. Risk assessment and breast cancer screening save lives. The USPSTF guidelines do not apply to women at high risk for breast cancer. Our genetic and high risk oncology programs at Fatima bint Bubarak Center at CCAD are leading the way in the management of high risk patients with modern, evidenced based practices and putting #patientsfirst
36 -
Malnati Brain Tumor Institute at Northwestern
"I truly believe that it's a privilege to be here at Northwestern and to be able to take care of each patient I interact with at a very difficult time during their journey with a cancer #diagnosis,"-Tarita Thomas MD, PhD. Meet Dr. Thomas, an MBTI #RadiationOncologist, in this video: https://lnkd.in/gY7ftFbT. #BTSM #RadOnc #BrainCancer #Oncology
9 -
Hamid Ghaznavi
Our chapter, "𝑳𝒐𝒘-𝒅𝒐𝒔𝒆 𝑹𝒂𝒅𝒊𝒂𝒕𝒊𝒐𝒏 𝑻𝒉𝒆𝒓𝒂𝒑𝒚 𝒇𝒐𝒓 𝑪𝑶𝑽𝑰𝑫-19 𝑨𝒔𝒔𝒐𝒄𝒊𝒂𝒕𝒆𝒅 𝑷𝒏𝒆𝒖𝒎𝒐𝒏𝒊𝒂: 𝑰𝒔 𝑻𝒉𝒆𝒓𝒆 𝑺𝒖𝒇𝒇𝒊𝒄𝒊𝒆𝒏𝒕 𝑺𝒖𝒑𝒑𝒐𝒓𝒕𝒊𝒏𝒈 𝑬𝒗𝒊𝒅𝒆𝒏𝒄𝒆?," is officially published in the book "𝑳𝒐𝒘 𝑫𝒐𝒔𝒆 𝑹𝒂𝒅𝒊𝒂𝒕𝒊𝒐𝒏 𝒊𝒏 𝑯𝒆𝒂𝒍𝒕𝒉 𝒂𝒏𝒅 𝑫𝒊𝒔𝒆𝒂𝒔𝒆" edited by Badri Narain Pandey, Nagraj G. Huilgol. This project wouldn't have been possible without the invaluable collaboration of my esteemed colleagues.
4 -
Robert Garofalo
9 years ago this month this piece ran in Chicago magazine on the creation of our gender development program at Ann & Robert H. Lurie Children's Hospital of Chicago. Life seemed simpler then. Healthcare was healthcare. The following is a nicely worded letter to the editor in yesterday’s The New York Times by Benjamin Hoffman, President of the American Academy of Pediatrics in response to the recently published Cass Report. 🙏👍 “Despite how it is often characterized, the AAP gender-affirming care policy statement calls for individualized health care for each patient, in consultation with their family and health care team. Dr. Hilary Cass suggests that American doctors should do what they are trained to do. We agree. The A.A.P. recommends that pediatricians care for gender-diverse young people the same way they care for all their patients. Critics of our policy often mischaracterize gender-affirming care as aggressively pushing medications or interventions. That is wrong. There are no predetermined treatments or timelines. Gender-affirming care begins with conversation, and it often goes no further than that. For many young people, having the space and time to explore their gender identity with the support of their loved ones and health care team is critical to their well-being. This health care approach integrates medical, mental health and social services, including resources and supports for parents and families. Dr. Cass says that politics should have no role in medical decision-making. We agree. In the U.S., politicians in over 20 states have placed their judgment ahead of parents and doctors by seeking to ban this care and criminalize those who provide it. Even following the publication of Dr. Cass’s report, no European country except Russia has fully banned the provision of gender-affirming care when medically necessary. Dr. Cass casts broad-scale doubt on existing research. We disagree. The evidence supporting our recommendations is far more nuanced than is represented in the interview. An independent review that is already underway will evaluate the body of evidence so the A.A.P. can continue to provide the best guidance to pediatricians. Dr. Cass’s conclusions will be considered in this review. The AAP will continue to follow the science and put patients and families first.” …and so will we at Lurie Children’s! Thank you AAP & Dr. Hoffman!!
2446 Comments -
Erfan Sheikhbahaei, MD
📣Another ground breaking finding for OAGB, this time for patients with BMI<35 with and without obesity-associated medical problems. “Biggest from a single center and large follow-up period”. ✅You may read this article on Surgical Endoscopy Journal of SAGES. 📍In summary: 1️⃣promising and sustainable weight loss throughout a 5-year period after OAGB; if your patient suffers from insufficient wright loss with diet+exercise you can recommend MBS 2️⃣high rates of remissions in DM, HTN,DLP 3️⃣predictable and previously known post-op complications not higher than what have been reported 4️⃣proper BPL length is a challenge; no relationship between BPLL and excessive weight loss or low Albumin level 5️⃣%EWL may not work the same as %TWL or Delta-BMI; we faced an EWL>100% without lab abnormalities 👇🏻Read more with details: https://lnkd.in/dnnP2AMj Thanks PIs, mentors, and congrats to our team Shahab Shahabi Mohammad Kermansaravi , MD, FAMIS, FIFSO Chetan Parmar #sages #ifso #asmbs #mbs #obesity #obesitysurgery #weightlosssurgery #oagb #rygb #sleeve
301 Comment -
milad khorasani
I am thrilled to share that my article titled "Angiotensin-converting enzyme I/D gene polymorphism and risk of type 2 diabetes mellitus in Iranian individuals" has been published! This research sheds light on the impact of genetic variations on the risk of developing type 2 diabetes among individuals in Iran. The study explores the association between angiotensin-converting enzyme gene polymorphism and the susceptibility to type 2 diabetes mellitus, providing valuable insights into the role of genetic diversity in determining diabetes risk within the Iranian population.
17 -
Ósìnákáchī Àkùmà Kálū
I read an interesting research paper last night titled, "Drug Interactions of Cola-Containing Drinks" by Homa Nomani, Ali Tafazoli Moghadam, Seyed Ahmad Emami, Amir Hooshang Mohammadpour, Thomas P. Johnston, and Amirhossein Sahebkar. The paper reviews the interactions between cola-containing drinks (CCDs) and drugs. CCDs are popular worldwide and have been reported to interact with some medicines. This paper aims to provide a comprehensive review of the subject. CCDs are known to be acidic and contain caffeine, which can potentiate interactions with different drugs. These interactions include changes in drug absorption, metabolism, and renal excretion. The paper reports toxic interactions between CCDs and several drugs, including MTX, clozapine, carbamazepine, phenytoin, and ibuprofen. It also discusses decreased efficacy when CCDs are taken simultaneously with lithium and warfarin. Finally, the paper suggests that CCDs may interact with numerous other drugs, and clinicians should be aware of these potential interactions to avoid adverse reactions and achieve the expected clinical response.
3 -
Shaghayegh Khanmohammadi
Check out our latest study entitled "Sex and age differences in inflammatory bowel disease patients; a nationwide study based on Iranian Registry of Crohn’s and Colitis (IRCC)", published in PLOS ONE! https://lnkd.in/dRiYMZ52 This study emphasizes the importance of understanding age and sex differences in IBD outcomes. These findings contribute to the ongoing global discussion on IBD management and facilitate the development of targeted interventions and personalized care. Many thanks to my supervisors, Dr. ozra Tabatabaei-Malazy and Dr. Alatab, and the other colleagues in this project! #IBD #cohort #research #gastroenterology
564 Comments
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More